ACE2 and gastric cancer: Based on the detailed survival information and ACE2 IHC staining of patients, we demonstrated that the protein expression levels of ACE2 were not correlated with the survival of patients with colon cancer (Figure 4A), gastric cancer (Figure 4B), pancreatic cancer (Figure 4C), or liver cancer (Figure 4D).